Abivax SA (ABVX)
Health Care
Abivax SA (ABVX) is listed on Nasdaq, where its shares have traded since October 20, 2023. SentiSense covers Abivax SA in the Health Care sector. Marc de Garidel is its chief executive officer. The company reports 69 employees, and its corporate website is www.abivax.com.
About Abivax SA
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 300 institutions reported holding ABVX, with 54.9 million shares worth $7.2 billion in aggregate. The largest reported holders were Tcg Crossover Management, Darwin Global Management, Ltd and Helikon Investments. Of the 5 largest reported holders, 4 added shares and 1 reduced its position during the quarter.
More on ABVX
- ABVX sentiment: whether news and social coverage of Abivax SA leans bullish or bearish, and the stories driving it.
- ABVX ownership: all 300 reporting institutions, plus insider and congressional trades.
- ABVX financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for Abivax SA: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Abivax SA do?
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
What sector is ABVX in?
SentiSense classifies Abivax SA in the Health Care sector.
Where does ABVX stock trade?
Abivax SA (ABVX) is listed on Nasdaq, where its shares have traded since October 20, 2023.
Who is the CEO of Abivax SA?
Marc de Garidel is the chief executive officer of Abivax SA.